von Minckwitz G, Costa S D, Blohmer J, Eiermann W, Jakisch C, Tulusan A H, Kaufmann M
Universitäs-Frauenklinik Frankfurt/Main.
Zentralbl Chir. 1998;123 Suppl 5:138-41.
Preoperative chemotherapy represents the standard procedure in inflammatory breast cancer. However, only recently it could be demonstrated that preoperative chemotherapy is beneficial even for patients with operable primary breast cancer. The number of breast conserving surgeries could be increased significantly. Furthermore this in vivo chemosensitivity assay can provide important prognostic as well as predictivy informations. Preoperative chemotherapy is not associated with an increased risk for the patients as outcome is similar to patients with conventional adjuvant treatment. We investigated new regimens to improve this type of chemotherapy and reached a remission rate of 93% with a combination of adriamycin and docetaxel (ADoc). A randomized study (GEPARDO-study) comparing ADoc with ADoc + tamoxifen has recently been started in Germany by the German Adjuvant Breast Cancer Study Group (GABG).
术前化疗是炎性乳腺癌的标准治疗程序。然而，直到最近才证实术前化疗对可手术的原发性乳腺癌患者也有益。保乳手术的数量可显著增加。此外，这种体内化疗敏感性检测可提供重要的预后及预测信息。术前化疗对患者而言并不增加风险，因为其结果与接受传统辅助治疗的患者相似。我们研究了新的方案以改进此类化疗，阿霉素与多西他赛联合使用（ADoc）达到了93%的缓解率。德国辅助性乳腺癌研究组（GABG）最近在德国启动了一项随机研究（GEPARDO研究），比较ADoc与ADoc加他莫昔芬的疗效。
